Onglyza (saxagliptin) belongs to drug class dipeptidyl peptidase-4 (DPP-4) inhibitor; it was approved by the U.S. Food and Drug Administration (FDA) on July 31, 2009. The drug was initially developed by Bristol-Myers Squibb; this was followed by AstraZeneca joining with Bristol-Myers Squibb in 2007 to co-develop the product and collaborating on the marketing front as well. Onglyza is prescribed for the treatment of Type-2 diabetes to be used along with diet and exercise to lower blood sugar in adults. Saxagliptin helps the pancreas to secrete more insulin and stops the liver from making excess sugar. Onglyza effectively controls the blood sugar without causing any weight fluctuations.
Studies conducted showed that people on Onglyza medication had a higher risk of pancreatic cancer and increased risk of hospitalization due to heart failure; thus, the medication has ended up causing more harm than benefit to diabetic patients.